Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jim has promised new plans in filing after filing over the years and the one constant is that nothing ever comes of it. No reason to think this time is different.
The HIV trial had 47 patients. Even with a perfect BLA it is not getting approved based on that.
The conference call was probably axed by attorneys trying to keep NP out of more hot water with the feds. At some point he has to realize the deep shit he's in.
The SEC can't close the investigation because NP keeps committing infractions.
Now that everybody knows the Vyera deal is not with Vyera anymore we've got no choice but to admit in the 10q that this happened for the first time in 2020. Sorry we didn't tell you.
And here's another "Chris Sandburg" article. Nothing suspicious about that.
The best defense is a good offense. Keep breaking the rules so the investigation never gets a chance to finish.
HaHa! As we discussed before Chris Sandburg wrote a piece about an obscure company called Bioxytran, a company that has listed Sheikh as the Executive Vice President of Business Development in SEC filings. Sheikh has pumped Bioxytran in articles under his name too.
And Vision and Value on Seeking Alpha has posted comments about Bioxytran too! Vision and Value posted 5 of the total 16 comments Bioxytran has ever had on SA. And 3 of the other comments were by the official Micheal Sheikh account! Sock puppetry? This guy is too obvious.
If "Chris Sandburg" is Michael Sheikh and there is evidence he is.
STOP POSTING ARTICLES YOU DUMMY. YOU ALL ARE UNDER INVESTIGATION.
It doesn't matter. They will still need another trial for MDR patients.
The BLA has never mattered because the trial only had 47 patients. It was never going to lead to an approval. Using monotherapy to bolster the trial is a NP fantasy. The FDA doesn't work that way. There will have to be another trial which means years until a possible HIV approval.
Brutal expose of Patterson and Yo with a little Cytodyn sliminess mixed in.
Exposes Patterson and Yo's quackery pushing expensive, unproven longhauler treatments that isn't covered by insurance. Also shoots down the simplistic thinking that it's all about the cytokines. Plus includes the nugget that Cytodyn is under SEC and DOJ investigations. And besides, as Patterson says...
“My concern has always been that there are other drugs out there that are just as good [as leronlimab],” he said, adding that Cytodyn doesn’t “realize how much competition there is out there.”
https://www.motherjones.com/politics/2022/01/desperate-patients-are-shelling-out-thousands-for-a-long-covid-cure-is-it-for-real/
Nader and Patterson with the race to the bottom. Nader has the head start but Patterson is right behind.
Updated numbers on Brazil trial patients
4 in critical trial
23 in severe trial
Scintillating numbers
Read your link. Those are only the top 20 pharmas and Nader made more than any of those CEOs with a total compensation of $9,971,254 last year.
https://www1.salary.com/Nader-Z-Pourhassan-Salary-Bonus-Stock-Options-for-CYTODYN-INC.html
In fact he made more than the CEOs of J&J, Roche, Pfizer, Novartis, Abbot and Abbvie did combined!
Pretty sure Sheikh is Chris Sandburg.
In addition to Cytodyn, Sandburg wrote a piece about an obscure company called Bioxytran, a company that has listed Sheikh as the Executive Vice President of Business Development in SEC filings. Sheikh has pumped Bioxytran in articles under his name too.
It's like an officer sending soldiers to battle knowing they had no ammunition for their weapons after he's been made the beneficiary of their death benefits.
New investor presentation available. BLA timeline has disappeared.
Poof. Gone. No more October 15.
Brazil trials not started.
https://d1io3yog0oux5.cloudfront.net/_a651bfcd20b4439ef4748bd8f7906851/cytodyn/db/193/3263/pdf/CytoDyn+-+Investor+Presentation_Updated+August-2021.pdf
Read the S-3. Cytodyn gets no money from those sales.
What Cytodyn has been doing is worse giving Fife shares at a discount month after month after month incentivizing him to short the stock and then sell. Rinse and repeat over and over.
Depends on the agreement between them and if that was a part of it or not and if they have a written contract or not.
Patterson has not deleted his tweets yet so he appears to be defying Naders complaint.
If Sidley Austin is so great why did they backtrack on 13D violating Cytodyn bylaws?
The first letter to Rosenbaum that was filed with the SEC as exhibit 99.1 was all about how 13D is out of luck because of the bylaws but the complaint concedes that this is untrue and now 13D has time to correct any errors they made.
Sloppy work by Sidley Austin.
Twitter fight goes to court. Great. Cytodyn is paying expensive attorneys fees in hopes of getting apologies.
The bullseye is clearly on Nader and crew.
Media is starting to cover the investigations
https://www.oregonlive.com/business/2021/07/vancouver-pharmaceutical-company-cytodyn-says-its-under-federal-investigation-over-covid-19-treatment-claims.html
We know why Nader was so desperate to cut corners and readout the nash trial early. I'm sure John Fife's lawyers are telling him to stay away from any more dealings with Cytodyn considering his own legal troubles with the SEC.
Yeah because lying to investors is what the cool CEOs do.
The SEC may be investigating Nader too. I filed a detailed complaint with the SEC against him last week. This is what the SEC said about their investigation into Nikola's CEO -
I filed a complaint with the SEC regarding false statements he's made in Proactive videos. I don't know if anything will come of it but the evidence is strong.
NP flat out lied in the last proactive video about patents. He said there were still 100,000,000 shares left to be issued when the CFO in the last conference call said there were only 62,000,000 shares left in February.
Do a google search for MTNBC median survival rates and see what you think.
Reading the literature those survival numbers are not improvements on the typical medians.
It's missing the word "Brazil".
28% of cos that got an RTF got a 2nd one according to an FDA study of RTFs 2008-2017.
Who else thinks it's inevitable that Nader gets a 2nd one?